The pharmacology of tissue oxygenation by biopure's hemoglobin-based oxygen carrier, Hemopure (HBOC-201).
Biopure's hemoglobin-based oxygen carrier, HBOC-201 (Hemopure), enhances oxygen transport by promoting both the convective and diffusive components of transport in the microcirculation. Convective transport is modified by HBOC-201 in three ways; (i) volume expansion promotes organ and tissue perfusion, (ii) the low viscosity of HBOC-201 improves flow to tissues, and (iii) oxygen delivery by HBOC Hb in the plasma is relatively insensitive to mechanisms regulating RBC distribution in the microcirculation. Diffusive oxygen transport is increased by the higher P50 compared with native RBC Hb which increases the off-loading of oxygen to tissues. Oxygen transport is also increased by reducing the diffusional barrier to oxygen transport associated with the plasma, in which oxygen is sparingly soluble. Biopure's HBOC solutions have been shown in vitro and in vivo to take up and off-load oxygen more efficiently than RBC Hb, and when added to blood can increase the efficiency of RBC oxygen transport.
Pearce
L Bruce
LB
Biopure Corporation, 11 Hurley Street, Cambridge, Massachusetts 02141, USA.
Gawryl
Maria S
MS
D001157:Arterial Occlusive Diseases / Q000188:drug therapy* / Q000378:metabolism; D001802:Blood Substitutes / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006438:Hemodilution; D006454:Hemoglobins / Q000378:metabolism*
D001802:Blood Substitutes; D006454:Hemoglobins; C096798:HBOC 201